metformin	is a	drug
metformin	treats	type 2 diabetes
metformin	reduces	hepatic gluconeogenesis
metformin	activates	AMPK
metformin	improves	insulin sensitivity
metformin	causes	lactic acidosis
metformin	contraindicated in	renal impairment
metformin	interacts with	cimetidine
metformin	dosage	500‑2000 mg/day
metformin	side effect	gastrointestinal upset
metformin	reduces	cardiovascular mortality
sulfonylureas	are a	drug class
sulfonylureas	stimulate	pancreatic β‑cells
sulfonylureas	cause	hypoglycemia
sulfonylureas	contraindicated in	severe renal disease
sulfonylureas	interact with	alcohol
sulfonylureas	dosage	glipizide 5‑30 mg/day
sulfonylureas	reduce	HbA1c
sulfonylureas	increase	body weight
DPP‑4 inhibitors	are a	drug class
DPP‑4 inhibitors	inhibit	DPP‑4 enzyme
DPP‑4 inhibitors	increase	GLP‑1 levels
DPP‑4 inhibitors	cause	mild hypoglycemia
DPP‑4 inhibitors	contraindicated in	severe renal impairment
DPP‑4 inhibitors	interact with	warfarin
DPP‑4 inhibitors	dosage	sitagliptin 100 mg/day
DPP‑4 inhibitors	reduce	HbA1c
DPP‑4 inhibitors	have	neutral weight effect
GLP‑1 agonists	are a	drug class
GLP‑1 agonists	mimic	GLP‑1 hormone
GLP‑1 agonists	reduce	appetite
GLP‑1 agonists	cause	nausea
GLP‑1 agonists	contraindicated in	pancreatitis
GLP‑1 agonists	interact with	oral contraceptives
GLP‑1 agonists	dosage	exenatide 5 µg BID
GLP‑1 agonists	reduce	HbA1c
GLP‑1 agonists	promote	weight loss
SGLT2 inhibitors	are a	drug class
SGLT2 inhibitors	inhibit	renal glucose reabsorption
SGLT2 inhibitors	cause	glucosuria
SGLT2 inhibitors	reduce	blood pressure
SGLT2 inhibitors	contraindicated in	type 1 diabetes
SGLT2 inhibitors	interact with	diuretics
SGLT2 inhibitors	dosage	dapagliflozin 10 mg/day
SGLT2 inhibitors	reduce	HbA1c
SGLT2 inhibitors	lower	heart failure risk
SGLT2 inhibitors	increase	genital infections
thiazolidinediones	are a	drug class
thiazolidinediones	activate	PPAR‑γ
thiazolidinediones	improve	insulin sensitivity
thiazolidinediones	cause	edema
thiazolidinediones	contraindicated in	heart failure
thiazolidinediones	interact with	warfarin
thiazolidinediones	dosage	pioglitazone 30‑45 mg/day
thiazolidinediones	reduce	HbA1c
thiazolidinediones	increase	body weight
metformin	reduces	hepatic glucose output
sulfonylureas	increase	insulin secretion
DPP‑4 inhibitors	prolong	incretin activity
GLP‑1 agonists	delay	gastric emptying
SGLT2 inhibitors	increase	urinary glucose excretion
thiazolidinediones	improve	adiponectin levels
metformin	improves	endothelial function
sulfonylureas	may cause	cardiac arrhythmias
DPP‑4 inhibitors	may reduce	cardiovascular events
GLP‑1 agonists	reduce	post‑prandial glucose
SGLT2 inhibitors	reduce	albuminuria
thiazolidinediones	may cause	bone fractures
metformin	contraindicated with	metronidazole
sulfonylureas	contraindicated with	sulfonamides
DPP‑4 inhibitors	contraindicated with	severe hepatic disease
GLP‑1 agonists	contraindicated with	thyroid C‑cell tumors
SGLT2 inhibitors	contraindicated with	pregnancy
thiazolidinediones	contraindicated with	liver disease
metformin	reduces	risk of ketoacidosis
sulfonylureas	increase	risk of hypoglycemia
DPP‑4 inhibitors	have	low hypoglycemia risk
GLP‑1 agonists	have	low hypoglycemia risk
SGLT2 inhibitors	have	low hypoglycemia risk
thiazolidinediones	have	low hypoglycemia risk
metformin	improves	lipid profile
sulfonylureas	worsen	lipid profile
DPP‑4 inhibitors	neutral	lipid profile
GLP‑1 agonists	improve	LDL cholesterol
SGLT2 inhibitors	improve	HDL cholesterol
thiazolidinediones	worsen	triglycerides
metformin	reduces	mortality in diabetes
sulfonylureas	no proven mortality benefit
DPP‑4 inhibitors	no proven mortality benefit
GLP‑1 agonists	reduce	mortality
SGLT2 inhibitors	reduce	mortality
thiazolidinediones	no proven mortality benefit
metformin	first‑line therapy	type 2 diabetes
sulfonylureas	second‑line therapy	type 2 diabetes
DPP‑4 inhibitors	third‑line therapy	type 2 diabetes
GLP‑1 agonists	third‑line therapy	type 2 diabetes
SGLT2 inhibitors	third‑line therapy	type 2 diabetes
thiazolidinediones	third‑line therapy	type 2 diabetes
metformin	improves	glycemic variability
sulfonylureas	increase	glycemic variability
